BDBM322106 1-[5-(Benzyloxy)-1-(1-cyclohexyl-2-fluoroethyl)-1H-pyrazol-3-yl]-N-methylmethanamine hydrochloride::US10183913, Example 330::US11312688, Example 330::US11576897, Example 330

SMILES CNCc1cc(OCc2ccccc2)n(n1)C(CF)C1CCCCC1

InChI Key InChIKey=DKTAXBXSANAKQY-UHFFFAOYSA-N

Data  7 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 322106   

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  0.960nMAssay Description:The [3H] citalopram binding was measured according to the method disclosed in Owens M. J. et al., J. Pharm. Exp. Ther., 283, 1305-1322 (1997). In spe...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  0.960nMAssay Description:Specifically, a solution containing 50 μL of [3H]-citalopram (GE Healthcare) diluted with SERT buffer (50 mmol/L Tris-HCl (pH=7.4) containing 12...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  2.80nMAssay Description:5-HT2A: A solution containing 50 μL of [H]-ketanserin (the final concentration: 1 nM), 2 μL of a solution of a test compound in DMSO or a s...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  17nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  17nMAssay Description:A solution of 200 μL in total was prepared by mixing 50 μL of [3H] mesulergine (manufactured by GE Healthcare) diluted with 50 mmol/L Tris-...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Target5-hydroxytryptamine receptor 2C(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM322106(US10183913, Example 330 | 1-[5-(Benzyloxy)-1-(1-cy...)
Affinity DataKi:  17nMAssay Description:5-HT2C: A solution containing 50 μL of [H]-mesulergine (GE Healthcare) diluted with 50 mmol/L Tris-HCl (pH=7.4) (the final concentration: about ...More data for this Ligand-Target Pair
In DepthDetails
US Patent